# PREDIKTOR REKURENSI KANKER PADA PASIEN DENGAN KARSINOMA SEL SKUAMOSA DI DAERAH KEPALA DAN LEHER

YS Wimardhani,\* DM Walker,\*\* JR Gibbins,\*\* MJ Veness,\*\* GJ Morga,\*\* II Kalnins\*\* \*Department Oral Medicine Faculty of Dentistry University of Indonesia \*\*University of Sydney Westmead Hospital NSW Australia

#### Abstract.

# Disease Recurrence Predictors for Patients with Head and Neck Squamous Cell Carcinoma

Information on reliable factors to predict patient outcome is important for deciding upon the best treatment to increase loco-regional control, overall survival and quality of life of patients with head and neck squamous cell carcinoma (HNSCC). The objective of this study was to investigate the role of clinicopathological parameters as predictors of disease recurrence in patients with HNSCC. We studied fifty patients who were seeking treatment for primary HNSCC in Westmead Hospital between 2002-2004. Univariate analysis was used to identify any significant association between clinico-pathological parameters and disease recurrence. It was showed that age (p=0.008), cTNM stage (p=0.02), size of tumour (p=0.009) and positive tumour margin (p=0.002) predicted the risk of the development of disease recurrence. In agreement with other studies we found that some traditional factors influenced disease recurrence. A longer follow-up study should be performed to assess the significance of these factors on overall survival as well as separate studies on prognostic indicators for patients with histologically negative lymph node. *Indonesian Journal of Dentistry 2006; Edist Khusus KPPIKG XIV:362-367* 

Key words: squamous ceil carcinoma, head and neck, predictor

#### Introduction

From recent data by Parkin et al.<sup>1</sup>, 499,000 new cancers of the head and neck (mouth and pharynx, larynx ICD-9 140-149, 161, see section 1.1.1) were registered per annum worldwide in 1990, accounting for 6% overall of new cancer cases. The relative global importance of head and neck cancers has slightly declined recently. In 1980 these cancers ranked as the sixth most common malignancy, whereas by 1990 they had become the eighth most common. However, during that time period the incidence of head and neck cancer had increased slightly in developed countries. <sup>2,3</sup> Head and neck cancers were three times more common in men than in women worldwide, estimated as the seventh most frequent cancer in males with 376,300 new cases worldwide and as the thirteenth most common in females involving 122,700 new cases.<sup>1,4</sup>

The etiology of head and neck squamous cell carcinoma is complex and a number of factors are known to increase the risk of malignancy. Oral cavity cancer has been found to be associated with alcohol and tobacco consumption in developed countries and also with the use of betel in developing countries. <sup>5,6</sup> Other risk factors such as

ultraviolet light particularly for lip cancer, dietary factors, viruses and a family history of head and neck cancer have also been implicated with head and neck carcinogenesis.

Generally, patients with HNSCC presented with stage I and II diseases with a clinically lymph node negative at the time of the diagnosis. Despite the negative node, histopathologically positive lymph nodes obtained from the neck dissection specimens were found in approximately one third of the cases. 7 Reduction to 50% of 5-year survival rate is seen when the regional lymph node metastasis is found.<sup>8</sup> The development of distant metastases (DM) in patients diagnosed with HNSCC carries a very poor prognosis with few patients surviving more than two years after the diagnosis.<sup>9</sup> Although distant metastases from HNSCC were previously considered uncommon, 4-25% of HNSCC patients have been found to have distant disease clinically or by imaging techniques with 25-47% found to have DM at autopsy.<sup>9-12</sup> With improving locoregional control of HNSCC, DM has assumed increased importance as a first site of relapse.

Therefore, information on reliable factors to predict patient outcome is important for deciding upon the best treatment to increase loco-regional control, overall survival and quality of life of patients with HNSCC. In the previous published studies, some factors which include clinical as well as pathological factors affecting patient outcome have been validated but there have also been conflicting results. This study aimed to identify any clinical or pathological features in the HNSCC patients in the present study which were associated with disease recurrence. The present study has identified several factors which were significantly associated with the development of disease recurrence. The result of this study would benefit clinician to decide the best possible treatment and follow-up for patients with increasing risk of developing disease recurrence.

#### Materials And Methods

#### Subjects

Fifty patients diagnosed with squamous cell carcinomas from the head and neck region during 2002-2004 were included in this study. All the participants in this study gave their signed informed witnessed consent. This study has been approved by the Western Sydney Area Health Service Human Research Ethics Committee and was carried out according to the Committee's recommendations. They were referred to the Head and Neck Cancer Service, Westmead Hospital, NSW, Australia.

#### Variables

The clinical and pathological variables were documented in each patient's hospital record and the details stored in the Department of Radiation Oncology were abstracted. Ethical approval was obtained from the Western Sydney Area Health Services Human Research Ethic Committees. The follow-up period for the 50 patients in this study started from the date of the beginning of treatment until disease recurrence or the completion of the study.

#### Statistical analysis

SPSS for Windows (Version 11.0) was used to analyze the data and the statistical analysis was performed with the assistance of Dr Karen Byth, Consultant Statistician, Westmead Hospital. Probability value of 5% or less was considered significant and probability value less than 10% was considered as approaching significance. Odds ratios (OR) and their 95% confidence intervals (CI) were used to quantify the degree of association.

The effect of clinical and pathological features of the HNSCC cases on disease recurrence was analyzed using Cox's regression model to assess their prognostic significance. Multivariate analysis was performed using the Cox's regression model, for variables found to be statistically significant or approaching significant by univariate analysis, to determine whether they had dependent or independent prognostic significance. Kaplan-Meier survival curves were built for the variables determined by multivariate analysis to be significantly associated with disease recurrence

### Results

Disease recurrence was recorded in 14 (28%) of 50 patients after completion of treatment. The results of statistical analysis of the correlation between clinico-pathological factors and disease recurrence are summarized in Table 1. The results showed that age, tumour stage, T stage, positive margin and perineural invasion were associated with the development of disease recurrence by univariate analysis.

Variable         Value of variable         p value         Hazard ratio         95% C1           1. Age (per year of age)         0.6         0.6         1.3         0.4-4.0           3. Smoking         Non-smokers         -         1         -           3. Smoking         Non-smokers         -         1         -           4. Alcohol consumption         Alcohol drinkers         0.6         1.4         0.4-5.0           5. Stage (per increase funce)         0.6         1.4         0.4-5.0           5. Stage (per increase funce)         0.002         1.9         1.3.3.3           6. T stage (per increase funce)         0.002         1.9         1.3.3.3           7. N stage (per increase funce)         0.01         1.4         0.6-6-5.5           8. Histology (+ vs - LN)         0.3         1.9         0.2-1.8           9. K S RT PCK (+ vs - LN)         0.3         1.9         0.2-5.4           10. Histology (single vs multiple)         0.9         1.1         0.3.3.5           12. Tumour grade         Low         -         -           13. Tamoer grade (per line code an eff)         0.3         0.9         0.5-4.7           14. EC (+ as.)         0.3         0.9         0.7-24.5	Univariate Con regression analysis Disease recurrence					
I. Age (per year of age)         c.008         L069         L018-L123           2. Gender         0.6         1.3         0.4-4.0           3. Smoking         Non-smokers         -         1           4. Alcohol consumption         Alcohol drinkers         0.5         2.1         0.3-17.4           4. Alcohol consumption         Alcohol drinkers         0.6         1.4         0.4-5.0           5. Stage (per increase targe)         0.0009         2.3         1.2-4.3           6. T stage (per increase Tatage)         0.009         2.3         1.2-4.3           7. N tage (per increase Tatage)         0.009         2.3         1.2-4.3           8. Histology (+ vs - LN)         0.3         1.9         0.2-1.8           9. K5 RT PCK (+ vr - LN)         0.3         1.9         0.2-1.8           10. Histology (single vs moltriple)         0.9         1.1         0.440.5           12. Tumour grade         Low         -         -         -           14. BCS (+ vr - L)         0.3         0.9         0.5-L1         0.7-24.5           15. Previous SCC         0.3         0.9         0.5-L1         0.7-24.5           15. Previous SCC         0.3         0.9         0.9-10.6         0.981-1087<	Variable Value of variable	p value	Hazard	95% CI		
Age (per year of age)       0.66       1.069       1.018-1.123         2. Gender       0.6       1.3       0.44.0         3. Smoking       Non-smokers       -       1         4. Alcohol consumption       Alcohol drinkers       0.5       2.1       0.5-36.0         5. Stage (per increase stage)       0.66       1.4       0.4-5.0         6. T stage (per increase stage)       0.002       1.9       1.1-3.3         6. T stage (per increase stage)       0.002       1.9       1.1-3.3         7. N tage (per increase stage)       0.002       1.9       1.2-4.3         8. Histology (+ vs - EN)       0.3       1.9       0.2-1.8         9. K S RT PCR (+ + - 1.6)       0.3       1.9       0.2-5.4         10. Histology (single vs multiple)       0.9       1.1       0.4-40.5         12. Tumour grade       Low       -       -         7. Tumour grade       0.3       0.9       0.5-1.7         13. Free on SCC       0.1       0.1       4.1       0.7-24.5         14. Fild       0.1       1.073       0.94-11.82         15. Previous SCC       0.1       0.3       0.9       0.5-1.7         16. Insegie/ (vs)       0.9       1.01 <th></th> <th></th> <th>ratio</th> <th></th>			ratio			
2. Gender       0.6       1.3       0.4-4.0         3. Smoking       Non-smokers       -       1       -         2. Allohold consumption       Ex-strokets       0.2       422       0.5-36.0         Chrrent smokers       0.5       2.1       0.3-17.4         4. Alcohol consumption       Alcohol drinkers       0.6       1.4       0.4-5.0         5. Stage (mer increase stage)       0.002       1.9       11-3.3         6. T stage (per increase stage)       0.009       2.3       1.2-4.3         7. N stage (per increase Tstage)       0.009       2.3       1.2-4.3         9. K 5 RT PCK (*** 1.b)       0.3       1.9       0.2-1.8         9. K 5 RT PCK (*** 1.b)       0.5       2.1       0.44.0.5         10. Histology (single vs multiple)       0.5       2.1       0.44.0.5         11. ECS (*** - 3)       1.0       -       -       -         12. Tumour grade       Low       -       1       -         13. State       0.9       0.9       0.5-1.7       0.6-12.9         14. Bitz       0.9       0.1       4.1       0.7-24.5         15. Previous SCC       0.1       2.3       0.8-7.1         15. Anternet st	1. Age (per year of age)	9.008	1.069	1.018-1.123		
Non-smokers       -       1       -         Ex-strokers       0.2       42       0.5-36.0         Current smokers       0.5       2.1       0.3-17.4         4. Alcohol consumption       Alcohol drinkers       0.6       1.4       0.4-5.0         5. Stage (ner increase stage)       0.0009       2.3       1.2-4.3         6. T stage (per increase stage)       0.009       2.3       1.2-4.3         7. M trade (per increase stage)       0.3       0.9       2.1       0.440.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8       0.3       1.9       0.2-1.8         9. K5 RT PCR (+ w - LN)       0.3       1.9       0.2-1.8       0.3       1.1       0.440.5         10. Histology (single vs multiple)       0.9       1.1       0.2-5.4       0.3       1.1       0.3-3.5         11. ECS (stars-2)       0.3       1.9       0.2-1.8       0.3       1.1       0.3-3.5         12. Tumour grade       Low       -       1       -       -       0.6-12.9       0.7       0.6-12.9         13. Ensister wa       0.1       2.3       0.7       0.6-12.9       0.1       2.3       0.8-7.1       2.4.3       0.8-7.1 <t< td=""><td>2. Gender</td><td>0.6</td><td>1.3</td><td>0.4-4.0</td></t<>	2. Gender	0.6	1.3	0.4-4.0		
Non-smokers       -       1       -         Ex-stricters       0.2       4.2       0.5-36.9         Current smokers       0.5       2.1       0.3-17.4         4. Alcohol consumption       Alcohol drinkers       0.6       1.4       0.4-5.0         5. Stage (per increase stage).       -       0.009       2.3       1.2-4.3         7. M tage (per increase Tstage)       0.1       1.4       0.6-6.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K 5 RT-PCK (+ vs - LN)       0.3       1.9       0.2-5.4         11. ECS (+ vs - 1)       0.9       1.1       0.3-35         12. Tumour grade       Low       -       1         7.3. Tumour grade       0.3       2.7       0.6-12.9         High       0.1       4.1       0.7-24.5         High       0.1       4.1       0.7-24.5         14. Size       0.9       0.9       0.5-1.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Magnetic value       0.06       3.2       0.9-10.6         17. Depth of invasion (per moi)       0.1       1.073       0.974-11.82         19. Perineural invasion <sup>4</sup>				e trade and age for the		
Ex-strokets         0.3         4.2         0.5-36.8           Current smokers         0.5         2.1         0.3-17.4           4. Alcohol consumption         Alcohol drinkers         0.6         1.4         0.4-5.0           5. Stage (per increase 1/stage)         0.009         2.3         1.2-4.3           6. T stage (per increase 1/stage)         0.1         1.4         0.6-6.5           8. Histology (+ vs = LN)         0.3         1.9         0.2-1.8           9. K5 RT PCK (+ vs = LN)         0.3         1.9         0.2-5.4           10. Histology (single vs multiple)         0.9         1.1         0.3-3.5           11. BCS (+ vs - L)         0.9         1.1         0.3-3.5           12. Tumour grade         Low         -         1           14. BCS (+ vs - L)         0.9         1.1         0.7-24.5           14. BCS (+ vs - L)         0.1         4.10         0.7-24.5           15. Previous SCC         0.1         2.3         0.8-7.1           16. Or invasion (per mm)         0.1         1.073         0.974-1.182           17. Depth of invasion (per mm)         0.1         1.075         0.981-1.059           18. Neurosting (Vs)         0.06         3.2         0.9-	3. Smoking Non-smokers	- 	] ••••••••••••••••••••••••••••••••••••	- 		
Current smokers       0.5       2.1       0.3-17.4         4. Alcohol consumption       Alcohol drinkers       0.6       1.4       0.4-5.0         5. Stage (per increase Tstage)       0.002       1.9       1.1-3.3         6. T stage (per increase Tstage)       0.009       2.3       1.2-4.3         7. M stage (per increase Tstage)       0.3       1.4       0.6-6.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K5 RT PCR (+ vs - LN)       0.3       1.9       0.2-5.4         10. Histology (single vs multiple)       0.9       1.1       0.2-5.4         11. ECS (****.)       0.3       1.4       0.7-24.5         12. Tumour grade       Low       -       -         13. Tomour grade       Low       -       1         14. Site       0.3       0.9       0.5-4.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Operineural invasion (per mm)       0.1       1.073       0.974.1.182         19. Perineural invasion*       0.05       3.2       0.9-10.6         19. Perineural invasion*       0.7       1.2       0.4-3.5         19. Perineural invasion*       0.7       1.2       0.4-3.	Ex-strokets	<b>6</b> 2	4.2	0.5-36.0		
4. Alcohol consumption       Alcohol drinkers       0.6       1.4       0.4-5.0         5. Stage (per increase stage)       0.002       1.9       1.1-3.3         6. T stage (per increase Tstage)       0.009       2.3       1.2-4.3         7. N stage (per increase Tstage)       0.3       9.1       1.4       0.6-6.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K5 RUPCK (+ vs - LN)       0.3       1.9       0.4-10.5         10. Histology (single vs multiple)       0.9       1.1       0.2-5.4         11. ES (+xx-)       0.3       1.9       0.2-7.4         12. Tumour grade       Low       -       -         13. Tumour grade       0.0       0.1       4.1       0.7-24.5         14. Site       0.3       0.9       0.5-4.7       0.6-12.9         15. Previous SCC       0.1       2.3       0.8-7.1         16. Stage (+x)       0.1       1.073       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         19. Perineural invasion*       0.3       1.9       0.3-7.7       0.4-3.5         17. Radiotherapy       0.7       1.2       0.4-3.5       0.2-3.5	Current smokers	<b>0.5</b> Selaki seti 5.04	2.1 Pagging and an	0.3-17.4		
4. Alcohol consumption       Alcohol drinkers       0.6       1.4       0.4-5.0         5. Stage (per increase stage)       0.009       2.3       1.2-4.3         6. T stage (per increase Tstage)       0.009       2.3       1.2-4.3         7. N stage (per increase Tstage)       0.1       1.4       0.6-6.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K 5 RT PCK (+ vs - LN)       0.3       1.9       0.2-5.4         10. Histology (single vs multiple)       0.9       1.1       0.3-3.5         12. Tumour grade       Low       -       -         14. EC (+ vs -)       0.1       4.1       0.7-24.5         12. Tumour grade (per laws of grave)       0.1       4.1       0.7-24.5         13. Tumour grade (per laws of grave)       0.1       4.1       0.7-24.5         14. Site       0.9       0.9       0.5-4.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Array of (vs v)       0.1       1.075       0.974-1.182         17. Depth of invasion (per min)       0.1       1.075       0.981-1.059         19. Perineural lawasion*       0.7       1.2       0.4-3.5         10.1       0.7 <t< td=""><td></td><td></td><td>regel in the</td><td>0450</td></t<>			regel in the	0450		
5. Stage (per increase Rage)       0.009       2.3       1.2-4.3         6. T stage (per increase Tstage)       0.1       1.4       0.6-6.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K.5 KI-PCR (+ vs - LN)       0.3       1.9       0.2-1.8         9. K.5 KI-PCR (+ vs - LN)       0.3       1.9       0.2-5.4         9. K.5 KI-PCR (+ vs - LN)       0.9       1.1       0.3-3.5         10. Histology (single vs multiple)       0.9       1.1       0.3-3.5         12. Tumour grade       Low       -       1         13. Tumour grade       0.2       2.7       0.6-12.9         14. Site       0.9       0.1       2       0.9-44.4         14. Site       0.9       0.9       0.9       0.9-10.6         15. Previous SCC       0.1       2.3       0.8-7.1         16. Marget 197       0.1       1.073       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Marget 197       0.0       3.2       0.9-10.6         19. Perineural invasion*       0.7       1.2       0.4-3.5         10. Additionary       0.7       1.2       0.4-3.5	4. Alcohol consumption Alcohol drinkers	0.0	1.4 I⊴∿⊊ à si	0.4-3.0		
6. T stage (per increase 1 stage)       0.009       2.3       1.2-4.3         7. M stage (per increase 1 stage)       0.1       1.4       0.6-6.5         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K.5 KT-PCR (+ vs - LN)       0.3       1.9       0.2-1.8         9. K.5 KT-PCR (+ vs - LN)       0.3       1.9       0.2-5.4         10. Histology (single vs multiple)       0.9       1.1       0.3-3.5         12. Tumour grade       1.0w       -       1       -         13. Tumour grade       0.2       2.7       0.6-12.9       -         14. Site       0.3       0.9       0.1       2.1       0.9-4.4.5         14. Site       0.3       0.9       0.5-4.7       0.8-7.1         15. Previous SCC       0.1       2.3       0.8-7.1         16. Margaet       0.9       0.1       1.073       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Margaet       0.06       3.2       0.9-10.6       0.9-10.6         19. Perineural invasion*       0.7       1.2       0.4-3.5       0.2431.1	5. Stage (per increase stage)	0.000	1.9	1243		
Notice (perturbative in state)       0.3       1.4       0.0-0.3         8. Histology (+ vs - LN)       0.3       1.9       0.2-1.8         9. K.5. RE-PCR (+ vs - LN)       0.3       2.1       0.4-10.5         10. Histology (single vs multiple)       0.9       1.1       0.2-5.4         11. EC.5 (* vs)       0.9       1.1       0.3-3.5         12. Tumour grade       10w       -       1         13. Tumour grade       10w       -       1         14. EC.5 (* vs)       0.1       4.1       0.7-24.5         13. Tumour grade (not not on grade)       0.1       4.1       0.7-24.5         14. Sola       0.9       0.1       2       0.9-4.4         15. Previous SCC       0.1       2.3       0.8-7.1         16. Option of invasion (per mm)       0.1       1.075       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.075       0.974-1.182         19. Perineural invasion*       0.0       3.2       0.9-10.6         19. Perineural invasion*       0.9       1.5       0.2-43.5         12. Radiotherapy       0.7       1.2       0.4-3.5	6. T stage (per increase Tstage)	0.009	2.3	1.2-4.3		
8. Histology (+ vs - LN)       0.3       1.9       0.241.6         9. K5 KF FCR (+ vs - LN)       0.3       2.1       0.4-10.5         10. Histology (single vs multiple)       0.9       1.1       0.2-5.4         11. EC (+ vs - LN)       0.9       1.1       0.3-3.5         12. Tumour grade       Low       -       1         13. Tumour grade       Low       -       1         14. EC (+ vs - LN)       0.9       1.1       0.2-5.4         14. EC (+ vs - LN)       0.9       1.1       0.3-3.5         12. Tumour grade       Low       -       1         14. EC (+ vs - LN)       0.0       0.1       4.1       0.7-24.5         15. Previous SCC       0.1       2.3       0.8-7.1         16. Histology (+ vs - mm)       0.1       2.3       0.8-7.1         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Version of invasion (per mm)       0.1       1.073       0.981-1.059         19. Perineural invasion*       0.0       3.2       0.9-10.6         19. Perineural invasion*       0.7       1.2       0.4-3.5         11. Ratiotherapy       0.7       1.2       0.4-3.5         15.	7. N stog (per mar ne stage)	0.2	1.0	0.0-0.3		
10. Histology (single vs multiple)       0.9       1.1       0.2-5.4         11. Et. 5 (4 vs.)       0.9       1.1       0.3.3.5         12. Tumour grade       10       10       0.1       0.1         13. Tumour grade       10       10       0.1       0.1         14. Et. 5 (4 vs.)       10       0.2       2.7       0.6-12.9         12. Tumour grade (per barriely statute)       0.1       4.1       0.7-24.5         14. Site       0.9       0.1       2.3       0.8-7.1         15. Previous SCC       0.1       2.3       0.8-7.1       0.8-7.1         16. Site       0.1       1.073       0.974-1.182       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Valuation (per mm)       0.1       1.073       0.974-1.182         19. Perineural invasion*       8.3       1       0.1-7.7         11. Radiotherapy       0.7       1.2       0.4-3.5         17. Consideration       0.7       1.2       0.4-3.5	8. Histology (+ vs – LN)	0.3 A 5	1.9	0.2-1.0		
10. Histology (single vs multiple)       0.9       1.1       0.2-3.4         11. ECS (stars)       9.9       1.1       0.3-3.5         12. Tumour grade       Low       -       1         13. Tumour grade       Low       -       1         14. ECS (stars)       1       -       -         13. Tumour grade       Low       -       1         14. Eds       0.1       4.1       0.7-24.5         14. Site       0.3       0.9       0.5-4.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Hurdet       0.1       2.3       0.8-7.1         17. Depth of invasion (per min)       0.1       1.073       0.974-1.182         18. Vacuum t and to of a construct       0.1       1.073       0.974-1.182         19. Perineural invasion*       0.06       3.2       0.9-10.6         24. Vacuum t dynamic for a construct       0.7       1.2       0.4-3.5         25. Construct       0.7       1.2       0.4-3.5         26. Construct       0.7       1.5       0.2411.1	X K) KI-PUK (* 75 LOU)	0.0	11 11	0.2-5.4		
12. Tumour grade       Low       -       1       -         12. Tumour grade       Low       -       1       -         14. Size       0.1       4.1       0.7-24.5         14. Size       0.1       2       0.9-4.4         14. Size       0.9       0.9       0.5-4.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Margative       0.1       2.3       0.8-7.1         17. Depth of invasion (per mm)       0.1       1.075       0.974-1.182         18. Vacuum and states       0.06       3.2       0.9-10.6         19. Perineural invasion*       0.7       1.2       0.4-3.5         21. Radiotherapy       0.7       1.2       0.4-3.5	10. Histology (single vs multiple)	0.9 8 <b>8 8</b>		0.2-5.4		
12. Tumour grade       100       1.00       1.7         13. Tumour grade (net lost op grade)       1.00       0.1       4.1       0.7-24.5         13. Tumour grade (net lost op grade)       0.3       0.1       2.1       0.9       0.9         14. Side       0.9       0.9       0.9       0.5-4.7       0.1       2.3       0.8-7.1         14. Side       0.9       0.1       2.3       0.8-7.1       2.2-33.3       0.1       1.073       0.974-1.182         15. Previous SCC       0.1       1.073       0.974-1.182       0.1       1.073       0.974-1.182         16. Margan       0.1       1.073       0.974-1.182       0.9       1       0.9881-1.055         17. Depth of invasion (per mm)       0.1       0.06       3.2       0.9-10.6       0.9       0.1-7.7         19. Perineural invasion*       0.06       3.2       0.9-10.6       0.1-7.7       0.4-3.5       0.2-311.1         21. Radiotherapy       0.7       1.2       0.4-3.5       0.2-311.1       0.2-311.1			n se			
High       0.1       4.1       0.7-24.5         14. Size       0.9       0.9       0.5-4.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Magint (***)       0.1       1.073       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Magint (***)       0.1       1.073       0.974-1.182         19. Perineural invasion*       0.06       3.2       0.9-10.6         21. Radiotherapy       0.7       1.2       0.4-3.5         23. Consideration       0.7       1.2       0.4-3.5	12. Tumour grade	e an	· · · ·	06179		
13. Transmit grade (ner horrisch grade)       0.1       2       0.9-4.4         14. Site       0.9       0.9       0.5-4.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Margar (vl.vl)       0.01       1.075       0.974-1.182         17. Depth of invasion (per mm)       0.1       1.075       0.974-1.182         18. Margar (vl.vl)       0.06       3.2       0.9-10.6         19. Perineural invasion*       0.7       1.2       0.4-3.5         20. Margar (vl.vl)       0.7       1.2       0.4-3.5	High	8.1×100	4 1	0 7-24.5		
14. Site       0.9       0.9       0.5-1.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Site gas       8.6       2.3-33.3         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. We construct the construction of	Lign	<b>A</b> 1	3	89.4.4		
14. Site       0.9       0.9       0.5-1.7         15. Previous SCC       0.1       2.3       0.8-7.1         16. Junt 1       8.6       2.3-33.3       0.9         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Out 1.0073       0.974-1.182       0.981-1.059       0.9         19. Perineural invasion*       0.06       3.2       0.9-10.6         20. cond. rhymphotic invasion       9.5       1       0.1-7.7         21. Radiotherapy       0.7       1.2       0.4-3.5         0.2411.1       0.9       1.5       0.2411.1		all delen a de la compañía	8868 (89 <del>7 -</del> 177 - 177 -	an a na manazi ya siya siya siya siya .		
15. Previous SCC       0.1       2.3       0.8-7.1         16. Margate(* var)       16. Margate(* var)       8.6       2.3-33.3         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Margate(* var)       0.1       1.073       0.974-1.182         19. Perineural invasion*       0.06       3.2       0.9-10.6         20. Vanish (fympholic keysion)       8.9       1       0.1-7.7         21. Radiotherapy       0.7       1.2       0.4-3.5         32. Consider 45.3       0.5       1.5       0.2411.1		0.00	0.9	0.5-17		
10. Interact (19. 1)       3.6       2.2-33.3         17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Via. mont are used at an are used at an area       0.1       1.019       0.981-1.059         19. Perineural invasion*       0.06       3.2       0.9-10.6         20. Visual references       9.9       1       0.147.7         21. Radiotherapy       0.7       1.2       0.4-3.5         0.2411.1       0.2411.1       0.2411.1	15 Previous SCC	0.1	2.3	0,8-7.1		
17. Depth of invasion (per mm)       0.1       1.073       0.974-1.182         18. Maximum complexity of the open for       6.1       1.019       0.981-1.059         19. Perineural invasion*       0.06       3.2       0.9-10.6         20. const r/jymphotic invasion*       0.7       1.2       0.4-3.5         21. Radiotherapy       0.7       1.5       0.2411.1	15. The violable control of the state of the		36	2238.3		
18 Maximum automode and for     6,1     1,019     6,981-1,059       19. Perineural invasion*     0.06     3.2     0.9-10.6       20. Venuel (Ayunghodic invasion)     9,9     1     9,1-7,7       21. Radiotherapy     0.7     1.2     0.4-3.5       6.9.2411.1	17 Denth of invasion (per mm)	0.1	1.073	0.974-1.182		
19. Perineural invasion*       0.06       3.2       0.9-10.6         20. voted r/tympholic invasion*       0.5       1       0.1-7.7         21. Radiotherapy       0.7       1.2       0.4-3.5         0.2411.1       0.1       0.2411.1	The second second second second second	6.1×	1,019	0.981-1.059		
19. Perineural invasion*       0.06       3.2       0.9-10.6         20. venuel r/tymphotic securities       0.9       1       0.1-7.7         21. Radiotherapy       0.7       1.2       0.4-3.5         22. Venuel r/tymphotic securities       0.3       1.5       0.2411.1			a sura can			
20. votest r/tympholic isostowi         0.9         1         0.1-7.7           21. Radiotherapy         0.7         1.2         0.4-3.5           0.7         1.5         0.2411.1	19. Períneural invasion*	0.06	3.2	0.9-10.6		
21. Radiotherapy 0.7 1.2 0.4-3.5	20. V mmt a //ymphotift interacion	. 19	8-1 S	0.1-7.7		
22 Consider 1998 201 201 201 201 201 201 201 201 201 201	21. Radiotherapy	0.7	1.2	0.4-3.5		
		$\leq 1 \leq 2\pi$	1.5	0.2-11.1		

۰.

 Table 1. Prognostic Factors Significantly Associated with an Increased Risk of Disease Recurrence in 50 Patients

 With HNSCC. Determined by Univariate Cox Regression Analysis

Key: + =positive; - =negative: vs=versus; F=female; M=male; LN=lymph node; CI=confidence interval;

Table 2. Prognostic Factors Significantly Associated with<br/>an Increased Risk of Disease Recurrence in 50<br/>Patients with HNSCC Determined by<br/>Multivariate Cox Regression Analysis

Multivariate Cox regression analysis					
Disease recurrence					
Variable	p value	Adjusted Hazard Ratio	95% CI		
<ol> <li>Age (per ycar of age)</li> </ol>	0.04	1.080	1.002-1.163		
2. Margin (+ vs -)	0.001	11.1	2.6-48.1		

Key: CI=confidence int ervat

Variables with prognostic significance or approaching prognostic significance by univariate analysis for disease recurrence were age, alcohol consumption, stage, cT stage, cN stage, tumour grade, previous history of HNSCC, margin, depth of invasion and perineural invasion were further analyzed ant the independent predictors found to be significantly associated with disease recurrence by multivariate analysis were age (per year of age) (p=0.04) and status of excision margin (p=0.001). (Table 2). Table 2 summarizes the factors significantly associated with disease recurrence determined by multivariate analysis.



Figure 1. Age (per year) was significantly associated with disease recurrence when analyzed using univariate Cox regression analysis (p=0.008) and determined as an independent predictor for disease recurrence by multivariate analysis (p=0.04).



Figure 2. The presence of tumour in the surgical margin assessed by histology was significantly associated with disease recurrence by univariate Cox regression analysis (p=0.002) and determined as an independent predictor for disease recurrence by multivariate analysis (p=0.004). At one year follow-up, patients with tumour in the surgical margin had 77% 1-year disease free survival rate compared with 38% of patients with negative tumour margin.

Kaplan Meier survival curves for disease recurrence of these two independent variables by multivariate analysis are shown in Figures 1, 2.

#### Discussion

In this study, some clinical and pathological features of the patients predicted the risk of the development of disease recurrence by univariate analysis. These variables were age, clinical TNM stage, clinical T stage, tumour margin and perineural invasion (Table1). These findings were similar to other results of previous investigations. <sup>13,14</sup> Furthermore, multivariate analysis revealed that age (per year of age) (p=0.04) and status of excision margin (p=0.001) were independently associated with the risk of disease recurrence.

A significant association between increasing age and disease recurrence was found by multivariate analysis in the present study. This observation was similar to those of other workers, <sup>13,14</sup> although these authors investigated homogeneous groups with carcinoma of the tongue. Further investigation on other factors related with patients' co-morbidity might help explained the results gained in this study.

Status of surgical margins was found to be a independently significant predictor for disease recurrence although the classification of positive surgical margins in this study did not include the specimens that have close margins (margin less than 0.5mm) and this finding was in concordance with previous results <sup>13,15-17</sup>. Some studies have reported contrary results, indicating that further molecular analysis to assess specific mutation in p53 gene in microscopically negative surgical margins was needed 18. A significant association between the findings of histologically lymph node metastases and disease recurrence was not found in this investigation. This result may reflect the success of the loco-regional control in the head and neck region with the application of adjuvant radiotherapy in patients with histologically positive lymph nodes <sup>19,20</sup> Four (29%) patients who experienced recurrences in this study did not have histologically positive lymph nodes and did not receive adjuvant radiotherapy however, Cox regression analysis showed that patients treated without radiotherapy had 1.2 times more likely to develop disease recurrences (Table 1). A short follow-up period in this study may also affect the lack of association

between histologically positive lymph nodes and disease recurrence.

A study with longer time period to continually monitor the patients included in this study is required. This would reveal the clinical relevance of the finding of disseminated tumour cells in lymph nodes. A five year follow up period of these patients may have shown the clinical relevance of the finding of these cells<sup>21</sup>, although a study of breast cancer suggested that patients should be followed up to twelve years to determine an accurate clinical significance of the presence of micrometastases.<sup>22</sup> The archival material of primary tumours of the patients included in this study could be used for further study to determine the expression of some metastatic markers within the specimen using immunohistochemistry.

## Conclusion

In agreement with other studies we found that some traditional factors influenced disease recurrence. A longer follow-up study should be performed to assess the significance of these factors on overall survival as well as separate studies on prognostic indicators for patients with histologically negative lymph node. •.

#### References

- Parkin D, Pisani P, Ferlay J. Estimates of the Worldwide Incidence of 25 Major Cancers in 1990. Int J Cancer 1999; 80:827-41.
- Schantz S, Yu G. Head and Neck Cancer Incidence Trends in Young Americans, 1973-1997, with a Special Analysis for Tongue Cancer. Arch Otolaryngol Head Neck Surg 2002; 128:268-74
  - Canto M, Devesa S, Oral Cavity and Pharynx Cancer Incidence Rates in the United States, 1975-1998, Oral Oncol 2002; 38:610-17
  - Parkin D, Pisani P, Ferlay J. Estimates of the Worldwide Incidence of Eighteen Major Cancers in 1985. Int J Cancer 1993; 54:594-606
- Murti P, Gupta P, Bhonsle R, Daftary D, Mehta F, Pindborg J. Effect on the Incidence of Oral Submucous Fibrosis of Intervention in the Areca Nut Chewing Habit. J Oral Pathol Med 1990; 19:99-100
- Sinor P, Gupta P, Murti P, Bhonsle R, Daftary D, Mehta F, Pindborg J. A Case-Control Study of Oral Submucous Fibrosis with Special Reference to the Etiologic Role of Areca Nut. J Oral Pathol Med 1990; 19:94-8
- 7. McDonald L, Walker D, Gibbins. Cervical Lymph Node Involvement in Head and Neck Cancer

Detectable as Expression of a Spliced Transcript of Type II Keratin K5. Oral Oncol 1998; 34:276-83

- Puri S, Fan CY, Hanna E. Significance of Extracapsular Lymph Node Metastases in Patients with Head and Neck Squamous Cell Carcinoma. *Curr* Opin Otolaryngol Head Neck Surg 2003; 11:119-23
- Calhoun K, Fulmer P, Weiss R, Hokanson J. Distant Metastases from Head and Neck Squamous Cell Carcinomas. Laryngoscope 1994; 104:1199-1205.
- Vikram B. Changing Patterns of Failure in Advanced Head and Neck Cancer. Arch Otolaryngol 1984; 110:564-5
- Bhatia R, Bahadur S. Distant Metastasis in Malignancies of the Head and Neck. J Laryngol Otol 1987; 101:925-8
- Snow G. Follow-up in Patients Treated for Head and Neck Cancer: How Frequent, How Thorough and For How Long? Eur J Cancer 1992; 28:315-6
- El-Husseiny G, Kandil A, Jamshed A, Khafaga Y, Saleem M, Allam A, Al-Rajhi N, Al-Amro A, Rostom A, Abuzeid M, Otieschan A, Flores A. Squamous Cell Carcinoma of the Oral Tongue: An Analysis of Prognostic Factors. Br J Oral Maxillofac Surg 2000; 38:193-9
- Yamazaki H, Inoue T, Yoshida K, Imai A, Yoshida Y, Tanaka E, Shimamoto S, Nakamura S, Inoue T, Nakamura H, Furukawa S, Shimizutani K. Influence of Age on the Results of Brachytherapy for Early Tongue Cancer. Int J Radiat Oncol Biol Phys 2001; 49: 931-6
- Smeele L, Leemans C, Langendijk J, Tiwari R, Slotman B, van Der Waal I, Snow G. Positive Surgical Margins in Neck Dissection Specimens in

Patients with Head and Neck Squamous Cell Carcinoma and The Effect of Radiotherapy. *Head Neck* 2000; 22: 559-63

- Jones K, Lodge-Rigal R, Reddick R, Tudor G, Shockley W. Prognostic Factors in the Recurrence of Stage I and Il Squamous Cell Cancer of The Oral Cavity. Arch Otolaryngol Head Neck Surg 1992; 118: 483-5
- Loree T, Strong E. Significance of Positive Margins in Oral Cavity Squamous Carcinoma. Am J Surg 1990;160:410-414
- Brennan J, Mao L, Hruban R, Boyle J, Eby Y, Koch W. Molecular Assessment of Histopathological Staging in Squamous-Cell Carcinoma of The Head and Neck. N Engl J Med 1995; 332:429-35
- Parsons J, Mendenhall W, Stringer S, Amdur R, Hinerman R, Villaret D, Moore-Higgs G, Greene B, Speer T, Cassisi N. Squamous Cell Carcinoma of the Oropharynx: Surgery, Radiation Therapy, or Both. Cancer 2002; 94: 2967-80
- 20. Smeele L, Leemans C, Reid C, Tiwari R, Snow G. Neck Dissection for Advanced Lymph Node Metastasis before Definitive Radiotherapy for Primary Carcinoma of The Head and Neck. Laryngoscope 2000; 110:1210-4
- Woolgar J. Micrometastasis in Oral/oropharyngeal Squamous Cell Carcinoma: Incidence, Histopathological Features and Clinical Implications. Br J Oral Maxillofac Surg 1999; 37:181-6
- Rosen P, Saigo P, Braun D, Weathers E, Brachia A, Kinney D. Maxillary Micro- and Macro Metastases in Breast Cancer. Ann Surg 1981; 194:585-91